Twist Bioscience Stock Surges As Anthropic AI Deal And Upbeat Guidance Reset Outlook

Twist Bioscience Corporation stocks have been trading up by 6.79 percent amid strong investor optimism following its latest developments.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TWST

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Q3 revenue hit $118.4M, beating $114.54M estimates with 23%+ growth, but the EPS loss widened to ($0.56) from ($0.33) year over year.
The company raised full-year fiscal 2026 revenue guidance to $456M–$457M and now targets gross margin above 52%, signaling stronger demand and better scaling.
Management guided Q4 revenue to $123M–$124M, well above $117.42M consensus, and aims for adjusted EBITDA breakeven in the quarter.
An upsized $300M equity offering at $96 per share boosts cash for R&D and manufacturing but adds near-term share supply and dilution.
Shares jumped roughly 17%–21% after selection by Anthropic for an AI-driven protein design project, underscoring sensitivity to AI-related catalysts.

Weekly Update Aug 17 – Aug 21, 2026: On Friday, August 21, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 6.79%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Twist Bioscience occupies a premium growth position in synthetic biology and DNA writing, with 5-year revenue CAGR near 28% and Q3 revenue up 23% YoY to $118.4M. Gross margin is excellent at ~78%, but EBIT margin of -31.5% and ROE of -30% underscore a still-immature profit model. Cash burn is moderating: Q3 operating cash flow turned positive at $1.1M, while free cash flow remains negative at -$8.6M. Balance sheet strength is solid (current ratio 2.7x, low leverage, $167M cash pre-offering) but valuation is extreme at ~22x sales and ~21x book, implying little tolerance for execution missteps.

Weekly price data show an aggressive uptrend, with closes stair-stepping from $117.69 to $145.59 within days, and a sharp breakout above the prior $120–$130 consolidation band. Intraday 5-minute tape (not shown here) has featured strong upside candles on expanding volume, confirming institutional demand rather than a thin squeeze. The dominant trend is decisively bullish; first high-conviction support sits near $135 (recent pullback low and breakout retest). For active traders, $135 is the key buy-the-dip level with a tight stop just below $130.

More Breaking News

Fundamentally, Twist is now executing above Healthcare and well ahead of the Medical Diagnostics & Screening group on revenue growth and margin trajectory, and numerous banks (TD Cowen, Piper, Baird) are converging around a $115–$120 fundamental anchor pre-Anthropic re-rating. Upsized $300M equity at $96 provides multi-year capital and validates institutional appetite, while the Anthropic AI-protein project adds a differentiated AI leverage story. Management’s guide to Q4 adjusted EBITDA breakeven and FY26 revenue of $456M–$457M compares favorably to sector peers that remain further from profitability. I assign a 12–18 month fair value range of $155–$165, with near-term resistance around $150 and strong technical support at $130–$135; risk-reward remains favorable despite volatility.

Quick Financial Overview

Twist Bioscience Corporation is showing classic high-growth, high-burn biotech dynamics that short-term traders can work with. Q3 revenue came in at $118.4M, beating expectations and growing more than 23% year over year, backed by a strong 77.9% gross margin. At the same time, the company printed a net loss of about $35.1M and a basic EPS of ($0.56), highlighting that profitability is still a work in progress despite improving operating leverage.

On guidance, Twist Bioscience raised its fiscal 2026 revenue outlook to $456M–$457M, ahead of prior guidance and Street expectations, and now targets gross margin above 52%. Management also guided Q4 revenue to $123M–$124M and is signaling adjusted EBITDA breakeven as soon as the current quarter. Key ratios confirm the picture: negative return on equity near -30% and an EBIT margin around -31.5%, but with a solid current ratio of 2.7 and modest total debt to equity of 0.24, liquidity risk looks manageable for now.

On the tape, TWST has been on a sharp upswing. Weekly prices moved from the high $110s into the mid-$140s, with the latest close near $145.59 after a string of strong sessions. Intraday, the 5-minute chart shows a steady intraday uptrend, with higher lows from the mid-$130s into the mid-$140s and persistent bids into the close, suggesting active momentum buying. Combined with a rich price-to-sales multiple around 21.9 and price-to-book over 21, this tells traders the stock is priced for continued execution and is likely to react strongly to any guidance surprises.

Conclusion

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!